Developing stationary phases for next-generation ²²⁵Ac/²¹³Bi generators

Targeted alpha therapy uses radionuclides to deliver radiation selectively to cancer cells, aiming to maximise therapeutic impact while limiting damage to surrounding healthy tissue. Among the radionuclides relevant to this approach, ²¹³Bi offers a short-lived, complementary option to the longer-lived ²²⁵Ac.